Hormones may play a role in bladder cancer. We evaluated the impact of a novel marker, the enzyme aromatase, on characteristics of bladder cancer in 40 patients. We found that expression of this enzyme was associated with higher tumor stage as well as survival outcomes. Our preliminary results should encourage further investigations into the role of hormones in bladder cancer. Background: Hormonal factors may play a role in bladder cancer (BCa). We investigated the expression of aromatase and estrogen receptor (ER)b and its association with pathological variables and survival outcomes. Patients and Methods: BCa specimens from 40 patients were evaluated. Immunohistochemistry was performed for aromatase and ERb. Descriptive statistics and univariate analyses assessed the association of these markers with pathologic variables and survival outcomes. Results: Aromatase expression was significantly associated with tumor stage; muscleinvasive disease was found in 15 of 19 (79%) patients with positive staining and in 7 of 18 (39%) patients with negative staining (P ¼ .02). Node-positive disease was found in 8 of 19 (42%) patients with positive staining and 1 of 18 (6%) patients with negative staining (P ¼ .01). After a median follow-up of 112 months, Cox regression analysis demonstrated that aromatase expression was associated with a more than 2-fold risk of cancer recurrence (hazard ratio, 2.37; confidence interval, 0.92-6.08; P ¼ .07) and an almost 4-fold higher risk of cancer-specific death (hazard ratio, 3.66; 95% confidence interval, 1.19-12.06; P ¼ .02). Muscle-invasive disease was found in 15 of 18 (83%) ERbpositive specimens and 4 of 12 (33%) ERb-negative specimens (P ¼ .0009). Hierarchical clustering analysis demonstrated a 4-fold up-regulation of ERb gene expression in tumor versus adjacent, non-tumor urothelium (P < .05). However, no significant association with survival outcomes was found. Conclusion: Aromatase expression in BCa may be associated with advanced tumor stage and poorer survival outcomes. ERb is upregulated in malignant tissue, and its expression is associated with muscle-invasive disease. These findings provide further evidence for the hormonal paradigm in BCa.
Introduction
Men are 3 to 4 times more likely to develop bladder cancer (BCa), 1 while women present with more advanced disease 2 and worse survival rates independent of stage. 3 Differential exposure to tobacco and occupational carcinogens has been postulated to explain the gender-related disparity in incidence. However, the difference persisted in a population-based analysis that controlled for these factors. 4 Genetic and anatomical factors, referral patterns for hematuria, and differences in treatment practices have also been advanced as contributors of differences in outcome between men and women with BCa.
More recently, hormonal factors have been postulated to explain the differential behavior of BCa between genders. The incidence of spontaneous and chemically induced bladder tumors in animals is greater in males than females and decreases with androgen deprivation. [6] [7] [8] The androgen receptor (AR) is expressed in human urothelium, and a progressive loss of expression with increasing pathologic stage of BCa has been reported. [8] [9] [10] [11] Against this background, some data suggest that estrogen receptor (ER)b, the main subtype of ER in the bladder urothelium, 12 may play a role in bladder carcinogenesis. [12] [13] [14] However, the available evidence on the biologic and prognostic significance of ERb is inconsistent. [10] [11] [12] 15, 16 To further expand on the subject, in this study we hypothesized that the enzyme aromatase, which is responsible for estrogen synthesis from androgen precursors, 17 may be a component of the hormonal paradigm in BCa. This has not been previously evaluated. Specifically, we assessed the association between aromatase and ERb expression in BCa with tumor pathology and long-term survival outcomes. In addition, we compared ERb gene expression in matched tumor and adjacent, non-tumor urothelium using DNA microarray technology.
Patients and Methods

Patients
Upon study approval by our Institutional Review Board, we evaluated tumor specimens from patients treated for urothelial carcinoma of the bladder from June 2002 to April 2005. A total of 40 patients with median age of 67 years (interquartile range [IQR], 59-73 years) were included, of which 27 (68%) were men and 13 (32%) were women. Tissue was collected at the time of transurethral resection (n ¼ 14; 35%) or radical cystectomy (n ¼ 26; 65%). Tumors were classified according to the 2002 TNM classification system 18 and graded using the 1998 World Health Organization/ International Society of Urological Pathology consensus classification. 19 The study investigators complied with the provisions of the Declaration of Helsinki and its subsequent modifications.
Immunohistochemistry
Immunohistochemistry for aromatase expression was performed on paraffin tissue sections with a monoclonal mouse anti-aromatase antibody (Serotec, Oxford, UK). Tissue localization of the ERb protein was performed on paraffin tissue sections using a polyclonal rabbit anti-ERb antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Staining was performed on the automated immunostainer TechMate 500 (Ventana Medical Systems, Tucson, AZ).
Briefly, formalin-fixed, paraffin-embedded tissue blocks were sectioned, deparaffinized, and rehydrated in a graded series of ethanol. Endogenous peroxidase activity was blocked with hydrogen peroxide in methanol. For aromatase, antigen retrieval was performed by heat with Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA) in a pressure cooker for 2 minutes. Nonspecific binding was blocked with 5% horse serum. Slides were then incubated with the primary mouse anti-aromatase antibody overnight at 4 C. Sections were then incubated with the secondary biotinylated affinity-purified horse anti-mouse IgG and treated with an avidin-peroxidase conjugated complex. Color was developed with 3,3 0 -diaminobenzidine substrate for 10 minutes. For ERb, antigen retrieval was performed in an autoclave using DAKO Target
Retrieval Solution (DakoCytomation, Carpinteria, CA). Slides were incubated with the primary rabbit anti-ERb antibody for 1 hour and with EnVision Plus-labeled Polymer-HRP anti-rabbit antibody (DakoCytomation) for 30 minutes. The peroxidase reaction was developed using DakoCytomation Liquid DAB plus Substrate Chromogen System (DakoCytomation). For both aromatase and ERb, sections were counterstained with hematoxylin, dehydrated, and mounted with Cytoseal-XYL (Richard Allan Scientific, Kalamazoo, MI). Negative controls were treated identically, except that mouse IgG was used instead of primary antibody for aromatase, and rabbit IgG was used instead of primary antibody for ERb. Negative controls for both aromatase and ERb showed an absence of staining. For aromatase positive control, formalin-fixed, paraffin-embedded placental tissue was used. For ERb, breast tissue was used. Immunohistochemistry for both aromatase and ERb was not performed on all patients because, in some cases, not enough tissue was available for research purposes.
Data Analysis and Outcome Measures
Aromatase and ERb expression were scored semiquantitatively by a single pathologist (B.D.R.) using standard light microscopy. A minimum of 500 cells from each tumor was evaluated. For aromatase, distinct, brown cytoplasmic staining, either granular or homogenous, was considered positive. For ERb, distinct, brown nuclear staining was considered a positive result. The percentage of cells staining positive was recorded. Results were categorized as negative (< 10% cell staining) or positive (> 10% cell staining). 12 Immunohistochemical analysis and pathologic evaluation were performed independently in a blinded fashion.
Clinical data were reviewed retrospectively from a prospectively maintained database. Our follow-up protocol comprised history, physical examination, urine cytology, and laboratory measurements every 3 to 4 months the first year, semi-annually for the second year, and annually thereafter. Additionally, office cystoscopy was performed for patients who underwent transurethral resection only. Diagnostic imaging was performed at least annually or when clinically indicated. Based on clinical and radiologic findings, cancer recurrence was defined as development of local recurrence after cystectomy, diagnosis of a new tumor after transurethral resection, or evidence of metastases after any intervention. For patients who died during the duration of the study, the cause of death was determined through review of medical records or death certificates.
Gene Expression Profiling
Gene expression analysis was performed in matched tumor and adjacent, non-tumor bladder specimens from 7 patients (14 specimens), of which 5 were men and 2 were women. Specimens were compared using DNA microarray technology as described previously. 20 Briefly, bladder specimens were placed in the embedding medium Tissue-Tek (Sakura Finetek) and stored at À70 C. RNA extraction was obtained using TRIzol reagent (Invitrogen, Carlsbad, CA) and Rneasy clean-up (Qiagen, Chatsworth, CA). RNA processing and hybridization protocols, as recommended by Affymetrix (Santa Clara, CA), were followed and are described in the Genechip Expression Analysis Technical Manual. RNA samples were fragmented randomly to approximately 200 bp. Each fragmented RNA sample was hybridized to the Affymetrix Human U133 A microarrays set. The microarray was washed, stained, and amplified according to the Affymetrix protocol.
Statistical Analyses
The c
For gene expression profiling, data normalization, log transformation, statistical analysis, and pattern study were performed using GeneSpring v 6.1 software (Silicon Genetics, Redwood City, CA). Statistical comparison between tumor and adjacent, nontumor urothelium was performed using the Welch t test with log transformed data. A 2-way hierarchical clustering by distance measure was used to group genes that were differentially expressed between tumor and non-tumor tissue.
Results
Aromatase Expression
Aromatase immunoreactivity was evaluated in 37 of the 40 patients and was found primarily in the cytoplasm ( Figure 1A , C, and E). Table 1 shows the patients' clinicopathologic characteristics and their association with aromatase staining. Of the 37 patients, 19 (51%) had some degree of staining for aromatase expression. There was no difference in aromatase expression between females and males, and After a median follow-up of 112 months for living patients (IQR, 50-123 months), 19 (51%) patients experienced disease recurrence and 15 (41%) patients died of disease. The Kaplan-Meier curves are shown in Supplemental Figure 1 (in the online version). Patients with aromatase-expressing tumors had greater probability of cancer recurrence (log rank P ¼ .057) and cancer-specific death (log-rank P ¼ .02). Univariate Cox regression analysis demonstrated that aromatase expression was associated with a more than 2-fold risk of cancer recurrence, although this did not reach conventional levels of significance (hazard ratio, 2.37; 95% confidence interval, 0.92-6.08; P ¼ .07) ( Table 2) . Furthermore, aromatase expression was significantly associated with an almost 4-fold higher risk of cancerspecific death (hazard ratio, 3.66; 95% confidence interval, 1.19-12.06; P ¼ .02).
ERb Expression
We evaluated 30 of 40 primary urothelial tumors for ERb expression. ERb immunoreactivity was localized to the nuclei, with weak staining evident in the cytoplasm ( Figure 1B , D, and F). Of the 30 patients, 18 (60%) had some degree of staining for ERb expression (Table 3) . Muscle-invasive disease was found in 15 of 18 (83%) ERb-positive specimens versus 4 of 12 (33%) ERb-negative specimens (P ¼ .0009). There was no association between ERb expression and tumor grade or nodal stage.
After a median follow-up of 89 months for living patients (IQR, 45-121 months), 17 of 30 (57%) patients experienced disease recurrence, and 13 (43%) patients died of disease. The Kaplan-Meier curves are shown in Supplemental Figure 2 (in the online version). ERb expression was not significantly associated with recurrence-free survival (log-rank P ¼ .4) or cancer-specific survival (P ¼ .2). Univariate Cox regression analysis showed that ERb expression was associated with a 1.5-fold higher risk of cancer recurrence, and a 1.9-fold higher risk of cancer-specific death, although this did not reach statistical significance (Table 4) . 
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DNA Microarray Analysis
Hierarchical clustering analysis demonstrated distinct gene expression patterns in tumor and adjacent, non-tumor urothelium from 7 patients (Figure 2) . We tested 22,283 genes, of which 496 demonstrated a significant difference between tumor and nontumor urothelium. ERb gene expression demonstrated a 4-fold up-regulation in tumor versus adjacent, non-tumor urothelium (P < .05).
Discussion
It is unknown whether a molecular basis for the gender difference in BCa presentation 2 and behavior 3 exists. Previous research focused mainly on the AR. [8] [9] [10] 21 Recent evidence suggested that the expression of ERb, which is the predominant receptor in bladder urothelium, 12 may represent another aspect of hormone-related bladder carcinogenesis. [10] [11] [12] [13] [14] 16 We extended these studies by demonstrating that the expression of aromatase is associated with advanced pathologic tumor classification and nodal disease. Accordingly, with a median follow-up of almost 10 years, aromatase expression was associated with an increased risk of recurrence and cancer-specific death. Aromatase is responsible for estrogen synthesis from androgen precursors, 17 and its expression in normal human bladder tissue has been previously suggested. 22, 23 Previous studies evaluating the role of AR in BCa generated conflicting results. While some authors reported loss of AR protein expression with increased stage and grade, [8] [9] [10] suggesting a role for AR in the early stages of BCa, others failed to demonstrate an association. 21 It could be postulated that it
is not AR that is of importance in hormone-related BCa. We anticipated that the aromatase/ERb concept may represent another aspect of the hormonal paradigm in BCa. The present data confirmed that ERb is associated with muscle-invasive tumors. 11, 12 In addition, our study is the first to document that ERb expression at the gene level is significantly upregulated in tumor versus adjacent, non-tumor urothelium. These findings suggest that ERb may have a promoting role during tumorigenesis. Unfortunately, despite our long follow-up, the sample size chosen for the study was likely too small to detect an association between ERb expression and survival outcomes. Tuygun et al, evaluating specimens from 139 patients with BCa, found no association between ERb expression levels and tumor grade and stage. However, only 33 (23%) patients had T2 classification, and none had > T2 disease. Nevertheless, the authors could show that lower ERb-expressing tumors had significantly better progression-free survival. 10 Along these lines, Kauffman et al 16 demonstrated an association between high ERb 24, 25 Estrogen synthesized by aromatase from testosterone in extragonadal tissues is locally active in a paracrine and intracrine fashion. 17 Thus, aromatase action can generate high local tissue concentrations of estrogen while circulating estrogen levels remain unaffected. 17 It has been documented that estrogen concentrations in breast tumors from post-menopausal patients are at least 20-fold greater than serum levels. 26 Further studies in breast cancer suggested that local estrogen production by aromatase is increased by overexpression of factors derived from the tumor stromal environment. 27 Our hypothesis is also supported by a previous study that demonstrated 5-alpha-reductase (5aR) expression in normal urothelium and urothelial carcinoma. 28 In this study, 5aR expression was found to be lower in cases of high-grade and high-stage urothelial carcinoma. Since 5aR metabolizes testosterone to dihydrotestosterone, a picture is emerging in which biologically aggressive BCa occurs in the setting of low 5aR and high aromatase expression, leading to elevated local estrogen levels ( Figure 3 ). Further studies investigating local tissue levels of androgens and estrogens in both normal and tumor urothelium in men and women will shed light on this issue.
Thus, locally increased estrogen could activate 1 or several pathways that modulate tumor behavior. Glucuronidation catalyzed by uridine diphosphate-glucuronosyltransferases (UGTs) represents a pathway of elimination of estrogens and androgens and, importantly of detoxification of carcinogens in BCa. 29 It was recently shown that androgen-dependent activation of the AR reduces the activity of UGTs located in the bladder urothelium, and that UGTs are upregulated in AR knockout mice. 30 These findings suggested BCa promotion through hormonal regulation of UGTs. They provide a background for similar experiments using anti-estrogens and aromatase inhibitors in in vitro and in vivo models of urothelial carcinoma. Our study has notable limitations. Owing to the relatively small sample size, we were unable to perform multivariable analysis to determine the independent predictive value of aromatase on survival outcomes. As mentioned above, the insufficient number of patients may also explain the lack of an association between ERb and survival. Our analysis is also limited by the inherent reliability of immunohistochemistry techniques such as choice of antibody, technical procedures, and interpretation criteria. These limitations notwithstanding, this study is the first to (1) evaluate aromatase in BCa and (2) show that ERb gene expression is significantly upregulated in tumor versus adjacent, non-tumor urothelium. Our results present an entirely new concept and add another piece to the puzzle; they thus indicate that additional investigations into the potential role of estrogens in BCa are warranted.
Conclusion
Aromatase expression in the urothelium of patients with BCa may be associated with muscle-invasive disease, nodal metastases, 
Clinical Practice Points
There is some evidence that hormonal factors may be involved in bladder carcinogenesis. An association between loss of AR expression and advanced pathologic stage has been suggested. Data on the biological and prognostic significance of ERb has been inconsistent. In this preliminary study, we took a step further and hypothesized for the first time that aromatase may play a role in bladder cancer. We found that expression of this enzyme was associated with tumor stage as well as long-term survival outcomes, in particular, cancer-specific death. In an area of research that is the subject of growing interest, our results provide a new concept that should form the basis for future, larger studies.
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